Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benzoyloxymethylthiamine is a lipophilic derivative and prodrug of thiamine (Vitamin B1). It was developed to enhance the bioavailability and tissue penetration of thiamine compared to standard water-soluble forms like thiamine hydrochloride. Upon administration, the compound is metabolized to release free thiamine, which is then phosphorylated to thiamine pyrophosphate (TPP), a vital cofactor for enzymes such as pyruvate dehydrogenase and transketolase. These enzymes are crucial for aerobic metabolism and energy production, particularly within the nervous system. Clinical research, primarily conducted in the late 1980s, demonstrated its efficacy in reducing the intensity and duration of postoperative pain following dental surgeries, such as third molar extraction, suggesting a role for high-dose thiamine derivatives in managing acute inflammatory pain and supporting nerve recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzoyloxymethylthiamine.